

QIP PY3.5 “Core QIP Metrics” Reporting Manual: General Guidance

C.	Proportionate Sampling	19
X.	Compliance Requirements	20
A.	Minimum Reporting Requirements	20
B.	Trending Breaks	20
C.	Multiple Hospital QIP Entities	20
D.	Data Integrity Policy	20
E.	Supporting Data/Documentation.....	20
F.	Audit Guidance.....	21
G.	Updating Enrollment Information.....	21
H.	Updating Beneficiary Contact Information via County Social Services	21
I.	Health Plan Data	21
XI.	QIP Reporting Mechanism.....	22
A.	Reporting Mechanism	22
B.	QIP Reporting Application: Access and User Guide	22
C.	Stratification of Reported Data by Age, Gender and Race/Ethnicity	28
D.	Medicaid Plan Specific QIP Performance Data.....	29
XII.	List of Acronyms	29
XIII.	QIP Measure Copyright Table.....	30
MEASURE SPECIFICATIONS		38
XIV.	Primary Care Measures	39
	PY3.5 Document Control Log – Primary Care Measures	41
Q-PC1:	Comprehensive Diabetes Care: A1C Control (CDC-H8)	42
Q-PC2:	Comprehensive Diabetes Care: Eye Exam (CDC-E)	42
Q-PC3:	Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP).....	42
Q-PC4:	Asthma Medication Ratio (AMR)	51
Q-PC5:	Medication Reconciliation Post Discharge (MRP)	56
Q-PC7:	Children and Adolescents’ Access to Primary Care Practitioners (CAP)	59
Q-PC9:	Immunizations for Adolescents (IMA), Combination 2	61
Q-PC10:	Childhood Immunization Status (CIS) Combination 10	65
Q-PC11:	Contraceptive Care: All Women (CCW) Most and Moderately Effective Methods, Ages 15-44	70
Q-PC12:	Chlamydia Screening in Women (CHL), Ages 16-24	75
	HEDIS Specification	75

QIP PY3.5 “Core QIP Metrics” Reporting Manual: General Guidance

Q-PC12: Chlamydia Screening in Women (CHL), Ages 16-24	78
eCQM Specification	78
Q-PC13: HIV Viral Load Suppression (HVL-AD)	88
Adult Core Set Specification	88
Q-PC13: HIV Viral Suppression (HVL-AD)	90
eMeasure Specification	90
Q-PC14: Well-Child Visits in the First 15 Months of Life (W15), Six or More Well-Child Visits	95
XV. Specialty Care Measures	99
PY3.5 Document Control Log – Specialty Care Measures	100
Q-SC1: Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	101
Q-SC2: Coronary Artery Disease (CAD): Antiplatelet Therapy	110
Q-SC3: Coronary Artery Disease (CAD): ACE Inhibitor or ARB Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)	117
Q-SC4: Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)	130
MIPS CQM Specification	130
Q-SC4: Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)	146
eCQM Specification	146
Q-SC5: Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	161
MIPS CQM Specification	161
Q-SC5: Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Nepriylsin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	177
eCQM Specification	177
Q-SC6: Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	191
MIPS CQM Specification	191
Q-SC6: Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	205
eCQM Specification	205
XVI. Inpatient Care Measures	220
PY3.5 Document Control Log – Inpatient Care Measures	221
Q-IP1: Surgical Site Infection (SSI)	222
Q-IP2: Perioperative Care: Selection of Prophylactic Antibiotic – 1st OR 2nd Generation Cephalosporin	227
Q-IP3: Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	235
Q-IP4: Prevention of Central Venous Catheter (CVC): Related Bloodstream Infections	245

QIP PY3.5 “Core QIP Metrics” Reporting Manual: General Guidance

Q-IP5: Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia	251
Q-IP6: Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)	257
TJC STK-2 Specification	257
Q-IP6: Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)	267
eCQM Specification	267
XVII. Resource Utilization Measures	273
PY3.5 Document Control Log – Resource Utilization Measures	274
Q-RU1: Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low-Risk Surgery Patients.....	275
Q-RU2: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older	281
Q-RU3: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years	288
Q-RU5: Concurrent Use of Opioids and Benzodiazepines	295
Q-RU6: Use of Opioids at High Dosage in Persons Without Cancer	300